AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20546160
Drug: Inhaled sevoflurane
RxNorm normalized name: sevoflurane Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled sevoflurane (IS)
Trial: 18184957
Drug: Hydrocortisone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (50 mg intravenous every 6 hours for 5 days, then tapered over 6 days)
Trial: 18184957
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered every 6 hours for 5 days, then tapered over 6 days)
Trial: 8643424
Drug: sCT (Miacalcic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCT (Miacalcic, Sandoz, nasal spray, 2 x 100 IU/day)
Trial: 8643424
Drug: sCT as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCT as the first active drug
Trial: 343181
Drug: PGE2‐analogue SHB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2‐analogue SHB 286 (50‐200 microgram extravular dose)
Trial: 343181
Drug: PGE2‐analogue SHB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2‐analogue SHB 286 (1000‐2000 microgram intravenous infusion)
Trial: 28885566
Drug: Cinnamon supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon supplement (3 g/day)
Trial: 23374027
Drug: BTDS 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTDS 20 μg/h (Butrans®)
Trial: 23374027
Drug: BTDS 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTDS 5 μg/h (Butrans®)
Trial: 19329221
Drug: Docetaxel 40
RxNorm normalized name: docetaxel 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 40 mg/m² days 1 and 8 plus gemcitabine 1200 mg/m² days 1 and 8 every 21 days (arm A)
Trial: 19329221
Drug: Docetaxel 50
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 50 mg/m² days 1 and 15 plus gemcitabine 1600 mg/m² days 1 and 15 every 28 days (arm B)
Trial: 19329221
Drug: Gemcitabine 1200
RxNorm normalized name: gemcitabine 1200 MG in 120 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1200 mg/m² days 1 and 8 plus cisplatin 100 mg/m² day 2 every 21 days for 3 cycles followed by docetaxel 75 mg/m² day 1 every 21 days for 3 cycles (arm C)
Trial: 11590384
Drug: Inhaled steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroid (440 microg fluticasone propionate [FP] twice per day)
Trial: 8724019
Drug: Hyperglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (blood glucose approximately equal to 15 mmol/l)
Trial: 30375104
Drug: Patches
RxNorm normalized name: Provent Hemp Patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patches
Trial: 30375104
Drug: Manual Pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Pressure Augmentation (MPA)
Trial: 19443246
Drug: Roland disability
RxNorm normalized name: Recombinant human rod-derived cone viability factor
DrugBank: FOV 2501 (DB17886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roland disability questionnaire (RDQ) administered at T1 and T2
Trial: 18188743
Drug: Nicotine craving,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine craving, withdrawal symptoms, and smoking urges measured daily for 30 days post-quit date.
Trial: 15933856
Drug: Dynamic exercise
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic exercise therapy
Trial: 11034583
Drug: SB-207266 (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-207266 (0.5, 5, and 20 mg doses)
Trial: 11034583
Drug: SB-207266 (0.05,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-207266 (0.05, 0.5, or 5 mg)
Trial: 8543503
Drug: Meropenem (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (10 to 20 mg/kg every 8 h)
Trial: 8543503
Drug: Cefotaxime (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (100 to 150 mg/kg/day), with or without amikacin or metronidazole
Trial: 2116610
Drug: GnRH-a (leuprolide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH-a (leuprolide acetate depot 3.75 mg every 28 days)
Trial: 28566400
Drug: Arthroscopic acromioplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic acromioplasty and supervised exercise treatment
Trial: 28566400
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise treatment alone
Trial: 26400874
Drug: Nighttime dosing
RxNorm normalized name: Flonase Nighttime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nighttime dosing of antihypertensive medications
Trial: 23755867
Drug: Ivabradine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine 2.5 mg
Trial: 23755867
Drug: Ivabradine 5
RxNorm normalized name: ivabradine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine 5 mg
Trial: 23755867
Drug: Ivabradine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine 10 mg
Trial: 19138567
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment (thioridazine, chlorpromazine, haloperidol, trifluoperazine, or risperidone) for 12 months
Trial: 19138567
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment (thioridazine, chlorpromazine, haloperazine, trifluoperazine, or risperidone) for 12 months
Trial: 19138567
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment (thioridazine, chlorpromazine, haloperidone, trifluoperazine, or risperidone) for 12 months
Trial: 18236771
Drug: Tailored psychosocial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored psychosocial and biological interventions
Trial: 7819171
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Latanoprost and Timolol
Trial: 7819171
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Timolol and Latanoprost
Trial: 31841417
Drug: Error Augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Error Augmentation (EA) in immersive VR
Trial: 31841417
Drug: Training without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Training without Error Augmentation (EA)
Trial: 25398701
Drug: Anti-arrhythmic medication
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-arrhythmic medication
Trial: 25398701
Drug: Non-selective beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective beta-blocker
Trial: 25398701
Drug: Other cardiovascular
RxNorm normalized name: INVESTIGATIONAL OTHER CARDIOVASCULAR DISEASES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other cardiovascular and psychotropic medication
Trial: 15321262
Drug: sufentanil 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil 7.5 microg (1.5 ml)
Trial: 15321262
Drug: sufentanil 5
RxNorm normalized name: SUFentanil 50 MCG in 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil 5 microg + bupivacaine 1 mg (1.5 ml)
Trial: 15321262
Drug: bupivacaine 1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 1.75 mg, sufentanil 1.05 microg and epinephrine 1.75 microg (1.5 ml)
Trial: 30636281
Drug: Gabapentin 800
RxNorm normalized name: gabapentin 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 800 mg (Neurontin)
Trial: 30636281
Drug: Gabapentin 800
RxNorm normalized name: gabapentin 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 800 mg (Gabasandoz)
Trial: 29049611
Drug: Prophylactic up‐front
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic up‐front surgery within 6 months from diagnosis combined with oncologic treatment
Trial: 29049611
Drug: Nonsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical treatment or delayed surgery as needed combined with oncologic treatment
Trial: 22253270
Drug: Remimazolam (0.01-0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam (0.01-0.3 mg/kg)
Trial: 22253270
Drug: Remimazolam (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam (6 mg initial loading dose followed by 3 mg maintenance doses)
Trial: 15728298
Drug: CoQ10 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (3 x 100 mg/day)
Trial: 9807845
Drug: Tramadol HCl
RxNorm normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol HCl 1.5 mg/kg
Trial: 7665860
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (Cefotaxime + Metronidazole)
Trial: 28035736
Drug: Whole-grain rye
RxNorm normalized name: rice (whole grain) allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-grain rye porridges (40 g)
Trial: 28035736
Drug: Whole-grain rye
RxNorm normalized name: rice (whole grain) allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-grain rye porridges (55 g)
Trial: 28035736
Drug: Rye porridge
RxNorm normalized name: Rye
DrugBank: Rye (DB10564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rye porridge enriched with inulin: gluten proportions (9:3 g)
Trial: 28035736
Drug: Rye porridge
RxNorm normalized name: Rye
DrugBank: Rye (DB10564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rye porridge enriched with inulin: gluten proportions (6:6 g)
Trial: 28035736
Drug: Rye porridge
RxNorm normalized name: Rye
DrugBank: Rye (DB10564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rye porridge enriched with inulin: gluten proportions (3:9 g)
Trial: 28035736
Drug: Refined wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined wheat bread (control, 55 g)
Trial: 25660206
Drug: Hypnotic suggestion
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic suggestion to sleep deeper before a midday nap
Trial: 23257734
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate 20 mg
Trial: 18805963
Drug: Recombinant asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant asparaginase preparation
Trial: 16407508
Drug: Benazepril 20
RxNorm normalized name: benazepril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 20 mg per day (group 1)
Trial: 16407508
Drug: Benazepril 20
RxNorm normalized name: benazepril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 20 mg per day (group 2)
Trial: 1505913
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (13 to 15 mg/kg body wt/day)
Trial: 22435936
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment group
Trial: 1375684
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no inotropic therapy)
Trial: 3965373
Drug: Retinyl acetate
RxNorm normalized name: RETINYL ACETATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl acetate (RA) gel 3 mg
Trial: 3965373
Drug: Retinyl acetate
RxNorm normalized name: RETINYL ACETATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl acetate (RA) gel 6 mg
Trial: 3965373
Drug: Retinyl acetate
RxNorm normalized name: RETINYL ACETATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl acetate (RA) gel 9 mg
Trial: 3965373
Drug: Retinyl acetate
RxNorm normalized name: RETINYL ACETATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl acetate (RA) gel 18 mg
Trial: 29575006
Drug: Molidustat 50
RxNorm normalized name: Molidustat
DrugBank: Molidustat (DB15642)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Molidustat 50 mg
Trial: 29575006
Drug: Molidustat (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molidustat (doses of 12.5 mg and above)
Trial: 29575006
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of molidustat
Trial: 26442829
Drug: TAC level(t)
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAC level(t) <4.0 ng/ml
Trial: 26442829
Drug: TAC level(t)
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAC level(t) ≥4.0 ng/ml
Trial: 24580383
Drug: Epidural 0.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural 0.75% levobupivacaine 12 ml with 1 ml (0.5 µg/kg) of dexmedetomidine
Trial: 24580383
Drug: Epidural 0.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural 0.75% levobupivacaine 12 ml with 1 ml of isotonic sodium chloride solution
Trial: 16697169
Drug: Lipidic physical
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipidic physical blend formulation (PB)
Trial: 12800415
Drug: Manshuailing Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manshuailing Oral Liquid (MSL) 100 ml, 2 times a day for 4 months
Trial: 12800415
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with western drugs (cardiotonic, diuretic, coronary dilator, etc.)
Trial: 12800415
Drug: Manshuailing Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manshuailing Oral Liquid (MSL) in patients with mixed heart failure (systolic and diastolic dysfunction)
Trial: 11193499
Drug: Intertrochanteric hip
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intertrochanteric hip fracture treatment
Trial: 9004441
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg GMDP
Trial: 9004441
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg GMDP
Trial: 9004441
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg GMDP
Trial: 9004441
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg GMDP
Trial: 29420997
Drug: l-carnosine 500
RxNorm normalized name: L-Carnosine
DrugBank: Carnosine (DB11695)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnosine 500 mg (2 capsules)
Trial: 20660002
Drug: Antithyroid drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drugs (medical treatment)
Trial: 20660002
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with TAO (regardless of treatment)
Trial: 18822620
Drug: Teriparatide 20
RxNorm normalized name: TERIPARATIDE 200UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 microg daily subcutaneously
Trial: 7560219
Drug: Triclosan pre-treatment
RxNorm normalized name: Triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triclosan pre-treatment before histamine application
Trial: 7012995
Drug: Bacampicillin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacampicillin (800 mg twice daily for 14 days)
Trial: 7012995
Drug: Ampicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (500 mg four times daily for 14 days)
Trial: 31522159
Drug: Alendronate (ALN)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN) at a dose of 70 mg once weekly for six months plus local debridement
Trial: 31522159
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of LS (1 gm tid for six weeks) and ALN (70 mg once weekly for six months) plus local debridement
Trial: 21239867
Drug: E170 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E170 insulin assay
Trial: 21239867
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of free insulin after PEG pre-treatment
Trial: 12938815
Drug: Galantamine 24
RxNorm normalized name: galantamine 24 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 24 mg per day
Trial: 10993031
Drug: HRT alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT alone (micronized E2 0.5 mg + micronized P4 100 mg)
Trial: 10993031
Drug: HRT +
RxNorm normalized name: Hormone Replacement Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT + T (micronized E2 0.5 mg + micronized P4 100 mcg + micronized T 1.25 mg)
Trial: 3909323
Drug: Aztreonam (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam (1-g or 2-g intravenous doses, three times daily for at least five days)
Trial: 3909323
Drug: Tobramycin (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (administered to a group of 34 patients)
Trial: 29415754
Drug: Guanxinning tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanxinning tablet (GXNT) plus aspirin for 12 months
Trial: 29415754
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone for 12 months
Trial: 29415754
Drug: Guanxinning tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanxinning tablet (GXNT) plus aspirin
Trial: 25399975
Drug: Danhong Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danhong Injection
Trial: 23597225
Drug: APF (1.23%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APF (1.23% acidulated phosphate fluoride gel)
Trial: 23597225
Drug: NNaF (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNaF (2% neutral sodium fluoride gel)
Trial: 16734505
Drug: Calcipotriene cream
RxNorm normalized name: Calcipotriene Cream
DrugBank: Calcipotriol (DB02300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcipotriene cream group
Trial: 16734505
Drug: Calcipotriene cream
RxNorm normalized name: Calcipotriene Cream
DrugBank: Calcipotriol (DB02300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcipotriene cream vs Vehicle
Trial: 16734505
Drug: Calcipotriene cream
RxNorm normalized name: Calcipotriene Cream
DrugBank: Calcipotriol (DB02300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcipotriene cream vs Vehicle (adverse reactions)
Trial: 14601366
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 15 mg/kg intravenous upon anesthetic induction, every 4 hours during surgery, and every 8 hours for 48 hours post-surgery
Trial: 2892988
Drug: Multivitamin/mineral supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin/mineral supplement administered for eight months
Trial: 2892988
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for eight months
Trial: 2892988
Drug: No tablets
RxNorm normalized name: caffeine Oral Tablet [No Doz]
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No tablets taken
Trial: 28485023
Drug: High-dose rituximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rituximab (HD-R) 1000 mg/m2
Trial: 28485023
Drug: Standard-dose rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard-dose rituximab (SD-R) 375 mg/m2
Trial: 28485023
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with ≤2 lines of treatment prior to SCT
Trial: 26362286
Drug: Resveratrol 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 500 mg orally once daily (with dose escalation by 500‐mg increments every 13 weeks, ending with 1,000 mg twice daily)
Trial: 23870300
Drug: Monthly ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly ranibizumab therapy
Trial: 23870300
Drug: Quarterly ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Quarterly ranibizumab therapy
Trial: 21608442
Drug: Myo-Inositol 2
RxNorm normalized name: myo-Inositol 2-dehydrogenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-Inositol 2 g twice a day
Trial: 21608442
Drug: D-chiro inositol
RxNorm normalized name: chiro-inositol, (+)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-chiro inositol 0.6 g twice a day
Trial: 19366435
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of M-M-RvaxPro and VARIVAX
Trial: 19366435
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of M-M-RvaxPro and VARIVAX
Trial: 11346153
Drug: Descalating dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Descalating dose of interferon-alpha-2a; six million units thrice weekly for 24 weeks followed by 3 MIU 3x for 24 weeks
Trial: 11346153
Drug: Interferon-alpha-2a (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha-2a (3 million units thrice weekly for 24 weeks) plus ribavirin (1,000 mg/day for 12 weeks)
Trial: 9214527
Drug: Pramipexole 1.5
RxNorm normalized name: pramipexole 1.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 1.5 mg/d